ElevateBio adds another $525M to its war chest as it looks to build on next-gen manufacturing 'basecamp'
Despite immense clinical promise, small cell and gene therapy players have faced a chronic manufacturing bottleneck tied to limited cash and specialized expertise. Born from the idea of disrupting the manufacturing business model in that space, ElevateBio has scored its biggest fundraising round yet to clear the logjam.
ElevateBio closed a massive $525 million Series C it will use to keep building its next-gen startup engine and one-stop-shop cell and gene therapy manufacturing “ecosystem,” the biotech said Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,500+ biopharma pros reading Endpoints daily — and it's free.